Abstract:Lymphatic malformations are linked to an elevation in inflammatory cells and cytokines, which aid in the stimulation of lymphatic alterations. Lymphangiogenesis, the process of generating new lymphatic vessels, enhances the movement of immune cells and cytokines from the site of inflammation. This mitigates inflammation and minimizes tissue damage. The lymphatic system, crucial for tissue fluid balance and immune surveillance, can be severely impacted by disorders that hinder its activities. Lymphatic malformations (LMs) are caused by fluid accumulation in tissues owing to defects in lymphatic channel formation, the obstruction of lymphatic vessels or injury to lymphatic tissues. Somatic mutations, varying in symptoms based on lesions' location and size, provide insights into their molecular pathogenesis by identifying LMs' genetic causes. In this review, we collected the most recent findings about the role of genetic and inflammatory biomarkers in LMs that control the formation of these malformations. A thorough evaluation of the literature from 2000 to the present was conducted using the PubMed and Google Scholar databases. Although it is obvious that the vascular endothelial growth factor receptor 3 mutation accounts for a significant proportion of LM patients, several mutations in other genes thought to be linked to LM have also been discovered. Also, inflammatory mediators like interleukin‐6, interleukin‐8, tumor necrosis factor‐alpha and mammalian target of rapamycin are the most commonly associated biomarkers with LM. Understanding the mutations and genes expression responsible for the abnormalities in lymphatic endothelial cells could lead to novel therapeutic strategies based on molecular pathways.

Genetic causes of lymphatic disorders: recent updates on the clinical and molecular aspects of lymphatic disease

A Narrative Review of Pathogenesis and Opportunities for Therapeutic Intervention

Complex Lymphatic Anomalies: Molecular Landscape and Medical Management

The Clinical Spectrum of Lymphatic Disease

Comorbidity and Lymphatic Disease: The Lymphatic Continuum Re-Examined

Lymphatic failure and lymphatic interventions: knowledge gaps and future directions for a new frontier in congenital heart disease

The lymphatics and the inflammatory response: lessons learned from human lymphedema

Lymphatic malformations: mechanistic insights and evolving therapeutic frontiers

Update and audit of the St George’s classification algorithm of primary lymphatic anomalies: a clinical and molecular approach to diagnosis

Histopathologic Features of Lymphedema: A Molecular Review

The role of key biomarkers in lymphatic malformation: An updated review

Lymphatic interventions in congenital heart disease

Lymphatic Dysfunction, Leukotrienes, and Lymphedema

Current and Developing Lymphatic Imaging Approaches for Elucidation of Functional Mechanisms and Disease Progression

Lymphoma classification update: B-cell non-Hodgkin lymphomas

The Lymphatic Highway: How Lymphatics Drive Lung Health and Disease

Recent insights into the genetic basis of systemic lupus erythematosus

A Review from Animal Disease Models to Clinics

Large Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment

Clinical Impact of the 2016 Update to the WHO Lymphoma Classification

Lymphatic System Development and Function